Impact of a switch from typical to atypical antipsychotic drugs on quality of life and gonadal hormones in male patients with schizophrenia

Neuroendocrinology Letters

Volumn 25, Issue 1-2, 2004, Pages 135-140

  Kaneda, Yasuhiro ^a,c   Kawamura, Ichiro ^b   Fujii, Akira ^b   Ohmori, Tetsuro ^a  

^a TOKUSHIMA UNIVERSITY HOSPITAL   (Japan)

^b Fujii Hospital   (Japan)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adverse events; Extrapyramidal symptoms (EPS); Hypothalamo pituitary gonadal (HPG) axis; Prolactin; Psychotic symptoms; Quality of life (QoL)

Indexed keywords

ESTRADIOL; NEUROLEPTIC AGENT; OLANZAPINE; PEROSPIRONE; PROLACTIN; QUETIAPINE; SEX HORMONE; BENZODIAZEPINE DERIVATIVE; DIBENZOTHIAZEPINE DERIVATIVE; INDOLE DERIVATIVE; THIAZOLE DERIVATIVE;

ANXIETY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DRUG SUBSTITUTION; ESTRADIOL BLOOD LEVEL; EXTRAPYRAMIDAL SYMPTOM; HOSPITAL PATIENT; HUMAN; MALE; PATIENT ASSESSMENT; QUALITY OF LIFE; RATING SCALE; SCHIZOPHRENIA; SCORING SYSTEM; SYMPTOMATOLOGY; ADULT; ANALYSIS OF VARIANCE; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG EFFECT; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; METABOLISM; PROSPECTIVE STUDY; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; SICKNESS IMPACT PROFILE; STATISTICS;

ADULT; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DIBENZOTHIAZEPINES; GONADAL STEROID HORMONES; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; INDOLES; MALE; PITUITARY-ADRENAL SYSTEM; PROLACTIN; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SICKNESS IMPACT PROFILE; STATISTICS; THIAZOLES;

EID: 3242807556     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Kaneda Y, Ohmori T. Impact of risperidone medication on quality of life and gonadal axis hormones in schizophrenia male patients with acute exacerbation. Int J Neuropsychopharmacol 2003; 6: 247-252.
2. Karow A, Naber D. Subjective well-being and quality of life under atypical antipsychotic treatment. Psychopharmacology (Berl) 2002; 162:3-10.
3. Voruganti L, Cortese L, Owyeumi L, Kotteda V, Cernovsky Z, Zirul S et al. Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study. Schizophr Res 2002; 57: 201-208.
4. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA 1999; 281:537-544.
5. Kaneda Y. Effects of risperidone on gonadal axis hormones in schizophrenia. Ann Pharmacother 2001; 35:1523-1527.
6. Knegtering H, van der Moolen AE, Castelein S, Kluiter H, van den Bosch RJ. What are the effects of antipsychotics on sexual dysfunctions and endocrine functioning? Psychoneuroendocrinology 2003; 28 Suppl 2:109-123.
7. Markianos M, Hatzimanolis J, Lykouras L. Switch from neuroleptics to clozapine does not influence pituitary-gonadal axis hormone levels in male schizophrenic patients. Eur Neuropsychopharmacol 1999; 9:533-536.
8. Kaneda Y, Taniguchi T, Ishimoto Y, Ohmori T. Effects of atypical antipsychotics on quality of life in patients with schizophrenia (in Japanese). Seishin Yakuryo Kenkyu Nenpo (Ann Rep Pharmacopsychiatry Res) 2002; 34:93-99.
9. Kaneda Y, Ohmori T. Quetiapine impact on quality of life in patients with schizophrenia. Ann Pharmacother 2003; 37:917-918.
10. Kaneda Y, Ohmori T. Effects of quetiapine on gonadal axis hormones in male patients with schizophrenia: a preliminary, open study. Prog Neuro-Psychopharmacol Biol Psychiatry 2003; 27:875-878.
11. Tomotake M, Taniguchi T, Kaneda Y, Ishimoto Y, Ohmori T. Effects of atypical antipsychotics on subjective quality of life in patients with schizophrenia (in Japanese). Seishin Yakuryo Kenkyu Nenpo (Ann Rep Pharmacopsychiatry Res) 2003; 35:99-105.
12. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV). Washington, D.C.: American Psychiatric Association; 1994.
13. Inagaki A, Inada T, Fujii Y, Yagi G. Dose equivalence of psychotropic drugs. Part 18. Dose equivalence of novel antipsychotics (3) Olanzapine (in Japanese). Rinsyo Seisin Yakuri (Jpn J Clin Psychopharmacol) 2001; 4:997-1000.
14. Inagaki A, Inada T, Fujii Y, Yagi G. ose equivalence of psychotropic drugs. Part 17. Dose equivalence of novel antipsychotics (2) Perospirone (in Japanese). Rinsyo Seisin Yakuri (Jpn J Clin Psychopharmacol) 2001; 4:869-870.
15. Inagaki A, Inada T, Fujii Y, Yagi G. Dose equivalence of psychotropic drugs. Part 16. Dose equivalence of novel antipsychotics (1) Quetiapine (in Japanese). Rinsyo Seisin Yakuri (Jpn J Clin Psychopharmacol) 2001; 4:681-684.
16. Inagaki A, Inada T, Fujii Y, Yagi K, Yoshio T, Nakamura H et al. Dose equivalence of psychotropic drugs (in Japanese). Tokyo: Seiwa Shoten Co., Ltd.; 1999.
17. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962; 10:799-812.
18. Inada T, Yagi G. Current topics in tardive dyskinesia in Japan. Psychiatry Clin Neurosci 1995; 49:239-244.
19. Guy W. ECDU assessment manual. Rockville: US Department of Health Education and Welfare; 1976.
20. Kaneda Y, Imakura A, Fujii A, Ohmori T. Schizophrenia Quality of Life Scale: validation of the Japanese version. Psychiatry Res 2002; 113:107-113.
21. Wilkinson G, Hesdon B, Wild D, Cookson R, Farina C, Sharma V et al. Self-report quality of life measure for people with schizophrenia: the SQLS. Br J Psychiatry 2000; 177:42-46.
22. Kinon BJ, Lieberman JA. Mechanisms of action of atypical antipsychotic drugs: a critical analysis. Psychopharmacology (Berl) 1996; 124:2-34.
23. Maguire GA. Prolactin elevation with antipsychotic medications: mechanisms of action and clinical consequences. J Clin Psychiatry 2002; 63 Suppl 4:56-62.
24. Kapur S, Zipursky R, Jones C, Shammi CS, Remington G, Seeman P. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry 2000; 57:553-559.
25. Turrone P, Kapur S, Seeman MV, Flint AJ. Elevation of prolactin levels by atypical antipsychotics. Am J Psychiatry 2002; 159:133-135.
26. Togo T, Iseki E, Shoji M, Oyama I, Kase A, Uchikado H et al. Prolactin levels in schizophrenic patients receiving perospirone in comparison to risperidone. J Pharmacol Sci 2003; 91:259-262.
27. Murasaki M, Koyama T, Machiyama Y, Yagi G, Kamijima K, Toru M, et al. Clinical evaluation of a new antipsychotic, perospirone HCL, on schizophrenia: a comparative double-blind study with haloperidol (in Japanese). Rinsho Hyoka (Clin Evaluation) 1997; 24:159-205.
28. Brown WA, Laughren TP, Williams B. Differential effects of neuroleptic agents on the pituitary-gonadal axis in men. Arch Gen Psychiatry 1981; 38:1270-1272.
29. Kaneda Y, Fujii A. Effects of chronic neuroleptic administration on the hypothalamo-pituitary-gonadal axis of male schizophrenics. Prog Neuro-Psychopharmacol Biol Psychiatry 2000; 24:251-258.
30. Franks S, Jacobs HS, Martin N, Nabarro JD. Hyperprolactinaemia and impotence. Clin Endocrinol (Oxf) 1978; 8:277-287.
31. Voruganti L, Heslegrave R, Awad AG, Seeman MV. Quality of life measurement in schizophrenia: reconciling the quest for subjectivity with the question of reliability. Psychol Med 1998; 28:165-172.
32. Priebe S, Roeder-Wanner UU, Kaiser W. Quality of life in first-admitted schizophrenia patients: a follow-up study. Psychol Med 2000; 30:225-230.
33. Harvey PD, Keefe RS. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry 2001; 158:176-184.
34. Drachman DA. Memory and cognitive function in man: does the cholinergic system have a specific role? Neurology 1977; 27:783-790.
35. Rao ML, Kolsch H. Effects of estrogen on brain development and neuroprotection-implications for negative symptoms in schizophrenia (1). Psychoneuroendocrinology 2003; 28 Suppl 2:83-96.